Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Total Debt (2016)

Historic Total Debt for Gyre Therapeutics (GYRE) over the last 8 years, with Q3 2016 value amounting to $28000.0.

  • Gyre Therapeutics' Total Debt fell 9585.8% to $28000.0 in Q3 2016 from the same period last year, while for Sep 2016 it was $28000.0, marking a year-over-year decrease of 9585.8%. This contributed to the annual value of $1.2 million for FY2015, which is N/A changed from last year.
  • Latest data reveals that Gyre Therapeutics reported Total Debt of $28000.0 as of Q3 2016, which was down 9585.8% from $130000.0 recorded in Q2 2016.
  • Over the past 5 years, Gyre Therapeutics' Total Debt peaked at $2.7 million during Q1 2012, and registered a low of $28000.0 during Q3 2016.
  • Moreover, its 5-year median value for Total Debt was $1.1 million (2013), whereas its average is $1.2 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Total Debt skyrocketed by 4142.26% in 2015, and later crashed by 9585.8% in 2016.
  • Gyre Therapeutics' Total Debt (Quarter) stood at $2.0 million in 2012, then tumbled by 42.83% to $1.1 million in 2013, then tumbled by 57.92% to $478000.0 in 2014, then soared by 141.84% to $1.2 million in 2015, then plummeted by 97.58% to $28000.0 in 2016.
  • Its last three reported values are $28000.0 in Q3 2016, $130000.0 for Q2 2016, and $196000.0 during Q1 2016.